Literature DB >> 15501759

Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies.

Fabien Brossier1, Martine Lévy, Annie Landier, Pierre Lafaye, Michèle Mock.   

Abstract

Protective antigen (PA) is central to the action of the lethal and edema toxins produced by Bacillus anthracis. It is the common cell-binding component, mediating the translocation of the enzymatic moieties (lethal factor [LF] and edema factor) into the cytoplasm of the host cell. Monoclonal antibodies (MAbs) against PA, able to neutralize the activities of the toxins in vitro and in vivo, were screened. Two such MAbs, named 7.5 and 48.3, were purified and further characterized. MAb 7.5 binds to domain 4 of PA and prevents the binding of PA to its cell receptor. MAb 48.3 binds to domain 2 and blocks the cleavage of PA into PA63, a step necessary for the subsequent interaction with the enzymatic moieties. The epitope recognized by this antibody is in a region involved in the oligomerization of PA63; thus, MAb 48.3 does not recognize the oligomer form. MAbs 7.5 and 48.3 neutralize the activities of anthrax toxins produced by B. anthracis in mice. Also, there is an additive effect between the two MAbs against PA and a MAb against LF, in protecting mice against a lethal challenge by the Sterne strain. This work contributes to the functional analysis of PA and offers immunotherapeutic perspectives for the treatment of anthrax disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501759      PMCID: PMC523002          DOI: 10.1128/IAI.72.11.6313-6317.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Point mutations in anthrax protective antigen that block translocation.

Authors:  B R Sellman; S Nassi; R J Collier
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

2.  Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.

Authors:  J Mogridge; M Mourez; R J Collier
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

3.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

4.  Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay.

Authors:  B Friguet; A F Chaffotte; L Djavadi-Ohaniance; M E Goldberg
Journal:  J Immunol Methods       Date:  1985-03-18       Impact factor: 2.303

5.  Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization.

Authors:  David Kobiler; Yehoshua Gozes; Hagai Rosenberg; Dino Marcus; Shaul Reuveny; Zeev Altboum
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 6.  Anthrax.

Authors:  M Mock; A Fouet
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

7.  Role of toxin functional domains in anthrax pathogenesis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

8.  Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.

Authors:  Jennifer A Maynard; Catharina B M Maassen; Stephen H Leppla; Kathleen Brasky; Jean L Patterson; Brent L Iverson; George Georgiou
Journal:  Nat Biotechnol       Date:  2002-06       Impact factor: 54.908

9.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

10.  Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process.

Authors:  Laurence Abrami; Shihui Liu; Pierre Cosson; Stephen H Leppla; F Gisou van der Goot
Journal:  J Cell Biol       Date:  2003-01-27       Impact factor: 10.539

View more
  52 in total

1.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

3.  An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Authors:  Nam-Kyu Lim; Jung-Hwan Kim; Mee Sook Oh; Sangyoon Lee; Se-Yeon Kim; Keun-Soo Kim; Hyun-Jung Kang; Hyo Jeong Hong; Kyung-Soo Inn
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1.

Authors:  Johanna Rivera; Antonio Nakouzi; Nareen Abboud; Ekaterina Revskaya; David Goldman; R John Collier; Ekaterina Dadachova; Arturo Casadevall
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.

Authors:  Ming Yan; Michael H Roehrl; Emre Basar; Julia Y Wang
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

6.  Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.

Authors:  Miriam M Ngundi; Bruce D Meade; Stephen F Little; Conrad P Quinn; Cindi R Corbett; Rebecca A Brady; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

7.  Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Authors:  Darrell E Singer; Rachel Schneerson; Christian T Bautista; Mark V Rubertone; John B Robbins; David N Taylor
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

8.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

9.  Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.

Authors:  Yong Sung Park; Jin Hyup Lee; Chien-Fu Hung; T-C Wu; Tae Woo Kim
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

10.  Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection.

Authors:  Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Bat-El Lachmi; Adva Mechaly; Shaul Reuveny; Orit Gat; Ohad Mazor; Arie Ordentlich
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.